Author | Year | Study design | Mean dose (mg/24 h) | Dose range (mg/24 h) | Findings |
---|---|---|---|---|---|
Molassiotis [47] | 2010 | survey study | no data | no data | second or third line for refractory chemotherapy-related nausea and vomiting |
Stephenson [48] | 2006 | non-comparative prospective study | no data | 6.25–25 | first line in indeterminate pathophysiological causes and second line for all other causes of nausea and vomiting |
Eisenchlas [13] | 2005 | open-label prospective study | 6.25 | 3.12- 25 | second line |
Amesbury [49] | 2004 | case report | no data | 12.5 -25 | first line indication: 5HT2 antagonist property of levomepromazine is used because large amounts of circulating 5-HT are present in carcinoid syndrome |
Kennett [50] | 2004 | quasi experimental prospective study | no data | 6.25-25 | second line or for indeterminate pathophysiological causes |
Higi [51] | 1980 | prospective study | no data | 16-30 | second line in chemotherapy induced nausea |
Davis [23] | 2010 | SR | nox data | no data | |
Glare [52] | 2004 | SR | no data | no data | based on one study [55] (not available) |